Roy S. Herbst, MD, PhD, on Personalized Immunotherapy for Lung Cancer: Expert Perspective
2018 ASCO-SITC Clinical Immuno-Oncology SymposiumRoy S. Herbst, MD, PhD, of the Yale School of Medicine, summarizes a session that included discussion of the mechanisms of immunotherapies, biomarkers for activity of these agents, overcoming resistance, and using treatment combinations.
Related Videos
Sumanta K. Pal, MD, on Renal Cancer Immunotherapy: Latest Developments
Sumanta K. Pal, MD, of the City of Hope, discusses immunotherapy as a front-line treatment for kidney cancer and the strategy of VEGF blockade with immunotherapy, which is emerging...
Linda Mileshkin, MBBS, on Solid Tumors: Early Treatment Study Results
Linda Mileshkin, MBBS, of the Peter MacCallum Cancer Centre, discusses phase Ib trial findings on the anti–PD-1 monoclonal antibody BGB-A317 in combination with the PARP inhibitor ...
Mary L. Disis, MD, on Basics of Immunology: An Overview
Mary L. Disis, MD, of the University of Washington, discusses innate and adaptive immune system cells, T cells as key to mediating antitumor immunity, and the mechanisms by which c...
Aaron Goodman, MD, on Immune Checkpoint Blockade: Clinical Implications
Aaron Goodman, MD, of the University of California, San Diego School of Medicine, discusses an analysis of more than 100,000 patients with cancer for CD274 (PD-L1) amplification an...
Kristen Fousek, PhD Candidate, on B-Cell ALL: CAR T-Cell Treatment
Kristen Fousek, PhD Candidate at Baylor College of Medicine, discusses her preclinical work on targeting CD19-negative relapsed B-cell acute lymphoblastic leukemia, using CAR T cel...
